Phase 4 N=250 Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis
Saphenous Vein Graft Disease
Primary: Saphenous Vein Graft Occlusion — 17.4; 13.2 percentage of veins occluded
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=46 Unique Effects of Perimenstrual Estradiol or Progesterone Supplementation on Perimenstrual Suicidality
Suicidal Ideation
Primary: Cyclical Change in Suicidal Ideation (SI) Severity — -.22; -.05; .25 units on a scale — p=.002
Phase 4 N=60 Trial Comparing the Onset and Duration of Ultrasound Guided Supraclavicular Nerve Blocks Using Ropivacaine Versus Ropivacaine-Chloroprocaine Mixture
Pain
Primary: Onset of Surgical Anesthesia — 16; 22; 9; 16 minutes
Phase 4 N=90 Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
Influenza Immunization · Healthy Volunteers
Primary: Number of Participants Aged 6 Months to <9 Years Who Provided Serum Samples for Analysis: Groups 1 and 2 — 28; 31; 20; 31 Participants
Phase 4 N=216 Stopping ACE-inhibitors in COVID-19
SARS-CoV-2 · COVID-19
Primary: Composite of the Maximum Sequential Organ Failure Assessment (SOFA) Score and Death Within 30 Days — 0; 1 score on a scale
Phase 4 N=223 A Phase IV Safety and Efficacy Study of VI-0521 in Adolescents With Obesity
Adolescent Obesity · Obesity in Adolescence · Adolescent Overweight
Primary: Mean % Change in Body Mass Index (BMI) — 3.34; -4.78; -7.11 Percentage Change — p=<0.0001
Phase 4 N=49 N-of-1 Trials In Children With Hypertension
Pediatric Hypertension
Primary: Number of Participants With Ambulatory Blood Pressure (BP) Control at 6 Months — 8; 8; 10; 15 Participants
Phase 4 N=17 Optimal Morphine Dosing Schedule for Neonatal Abstinence Syndrome
Neonatal Abstinence Syndrome · Neonatal Opioid Withdrawal · Neonatal Opioid Withdrawal Syndrome
Primary: Enrollment Rate — 17 Participants
Phase 4 N=46 Effects of Delta-9 Tetrahydrocannabinol (THC) on Retention of Memory for Fear Extinction Learning in PTSD: R61 Study
PostTraumatic Stress Disorder
Primary: Brain Measures — 0.039567327; 0.092173636; 0.149446357; -0.021618 arbitrary units — p=< 0.05
Phase 4 N=333 Evaluation of VISITAG SURPOINT™ Module With External Processing Unit (EPU)
Paroxysmal Atrial Fibrillation
Primary: Number of Participants With Primary Adverse Events (PAEs) — 11; 3 Participants
Phase 4 N=44 Pilot Study to Collect and Evaluate Data on the Use of IV* Ibuprofen in the Treatment of an Acute Migraine Attack
Episodic Migraine
Primary: Comparison of Proportion of Subjects in Control and Active Treatment Groups Who Have Pain Relief at 2 Hours After the Completion of the Double-blind Treatment Infusion…
Phase 4 N=49 Comparison of Single-Dose Efficacy of an Albuterol Breath-Actuated Inhaler (Albuterol-HFA-BAI) Versus an Albuterol Metered-Dose Inhaler (Albuterol-HFA-MDI) in Participants With Asthma
Asthma
Primary: Area-Under-the-Effect Curve of Percent Change in Test-Day Baseline Forced Expiratory Volume in 1 Second (FEV1) Versus Time (up to 2 Hours Postdose), %FEV1 AUEC0-2…
Phase 4 N=46 Regional Anesthesia to Reduce Opioid Use Following Functional Endoscopic Sinus Surgery
Pain Management
Primary: Participant Pain Control — 4.5; 5.87; 4.63; 5.00 units on a scale — p=0.16
Phase 4 N=40 Tramadol Extended-Release (ER) for Posttraumatic Stress Disorder (PTSD)
Post-Traumatic Stress Disorder
Primary: Clinician-Administered PTSD Scale (CAPS) — 79.1; 81.9; 90.0; 91.0 units on a scale — p=0.286
Phase 4 N=6 Pimavanserin for Insomnia In Veterans With Posttraumatic Stress Disorder
Post-traumatic Stress Disorder · Insomnia
Primary: Recruitment Rates — 1.03 participants enrolled per month